2019 Executive Sponsors
2019 Associate Sponsors
2019 Supporting & Educational Partners
2019 Media Partners
2019 Executive Sponsors
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. Learn more at www.adaptivebiotech.com.
Imaging Endpoints (IE) is a mission driven research and imaging CRO with offices in Scottsdale, Arizona and Waltham, Massachusetts. We specialize in providing the industry’s leading imaging expertise and most advanced technologies coupled with exquisite services. Our experience extends from translational to phase 3 trials and every step in-between. Our organization is unique in that it is owned by a team of over 40 in-house radiologists and nuclear medicine physicians that specialize in advanced imaging technologies. Our comprehensive services span all aspects of trial planning and conduct, including protocol development, site qualification and standardization, real-time image receipt/QC and reads, data management, regulatory compliance and preparation for meetings/submissions to regulatory authorities. Our Rapid Detection and Assessment of Response program (RaDAR) is designed to accelerate product development by integrating the most advanced imaging technologies into clinical trials. At Imaging Endpoints, our capabilities go above and beyond the typical imaging core lab offering. Learn more at www.imagingendpoints.com.
Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our phenotypic CANscript platform
NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-licensed facilities across the US, but work hard to maintain easy access and all the efficiencies of a smaller operation. Visit www.neogenomics.com.
Q2 Solutions is a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. With a relentless focus on quality and innovation, Q2 Solutions uses its global experience and scientific expertise to transform science and data into actionable medical insights that help customers improve human health. A joint venture of IQVIA (formerly QuintilesIMS) and Quest Diagnostics, Q2 Solutions combines the best of each parent organization’s clinical trials laboratory services capabilities to fulfill its mission of treating each sample as if a life depends on it. Learn more about us at www.q2labsolutions.com.
2019 Associate Sponsors
Defined Health is a scientifically staffed strategic business development advisory service with 30+ years of experience. Our core business includes evaluating assets in development (compounds or platform technologies) and providing our clients with independent, objective, well respected forecasts in advance of their licensing or funding negotiations; identifying opportunities; assisting in prioritization and sequencing of indications, and assisting companies with early commercial strategy issues. We have extensive experience in understanding the unique challenges of product development, regulation, market access and commercialization across the therapeutic area landscape. We bring together deep scientific understanding of the potential to translate novel therapeutic approaches into clinical and commercial value and understand payer needs and innovation in reimbursement strategies to ensure patient access to unique breakthrough therapies. Learn more at definedhealth.com.
mint Lesion™ analysis software provides comprehensive, compliant response assessment for clinical trials and routine radiology assessment. With an extensive array of standardized response criteria (RECIST 1.1, immune-response, Lugano, RANO, etc), Mint Lesion™ facilitates research using robust response algorithms, data analytics/mining, radiomics and the simplified provision of results. Mint Lesion™ is used worldwide for cancer centers, pharma/biotech, imaging CROs and radiology practices. Learn more at www.mint-medical.com.
Provecs Medical is an innovative immune-oncology company founded in Hamburg, Germany. Provecs develops unique multivalent immunotherapeutics to reprogram the tumour microenvironment. Core technologies: the adenoviral platform ENVIRO and the proof-of-concept platform EXVIRO for lead identification and qualification applying high through-put technologies like transcriptome profiling, bioinformatics, and tissue immune imaging technologies. Learn more at www.provecs.com.
Caprion is a specialty CRO providing laboratory services to pharmaceutical/biotechnology companies with GCP/GLP/GCLP capabilities. Caprion’s ImmuneCarta® Division, offers multi-parametric flow cytometry, cytokine testing, and ELISpot for analyses of innate and adaptive immune responses. Caprion’s ProteoCarta™ Division leverages its expertise in mass spectrometry for protein analysis in support of biomarkers development. Learn more about us at www.caprion.com.